top of page

Unmet Need

Current treatments fail up to 50% of nAMD patients, resulting in significant vision loss or blindness. Additionally, up to 67% of patients still experience persistent retinal fluid after two years of treatment.

​

Prevalence and Incidence: Approximately 1.5-1.7 million Americans are affected,     

with around 300,000 new cases annually.

iStock-1308485052_edited.jpg

Innovative Solution

Orsight Pharma is developing a First-in-class drug aimed at preserving vision and preventing blindness through a breakthrough mechanism, offering new hope for those unresponsive to existing treatments.

​

- Small Molecule Advantage

- Prevents Blindness Through a Unique Mechanism

- Slow Release Formulation     

- Complementary to Current Treatments

​

bottom of page